| Clinical Evaluation of Detection of High Risk HPV in Urine (NCT05210348) | Peking University People's Hospital | 2021-09-15 |
| Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical Carcinoma (NCT05013268) | Ruijin Hospital | 2021-09-01 |
| Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma (NCT04976478) | Peking University Third Hospital | 2021-07-01 |
| A Prospective Study of the Early Treatment of Recombinant Human Thrombopoietin for Chemoradiation Induced Thrombocytopenia in Cervical Squamous Cell Carcinoma Patient (NCT07649395) | Mei Feng | 2021-02-01 |
| Nimotuzumab Combined With Chemoradiotherapy Versus Chemoradiotherapy for Local Advanced Cervical Squamous Cell Carcinoma (NCT04678791) | Peking University Third Hospital | 2020-12-01 |
| Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma (NCT07147361) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2020-05-28 |
| Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. (NCT03983954) | NeoTX Therapeutics Ltd. | 2019-10-10 |
| Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer (NCT03738228) | National Cancer Institute (NCI) | 2019-01-07 |
| Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma (NCT06781073) | Biotech Pharmaceutical Co., Ltd. | 2017-07-06 |
| Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (NCT02466971) | National Cancer Institute (NCI) | 2016-05-10 |
| Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations (NCT02646319) | Mayo Clinic | 2016-01-01 |
| Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer (NCT02562729) | Shanghai Gynecologic Oncology Group | 2015-09-01 |
| Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers (NCT02020707) | Mayo Clinic | 2014-02-24 |
| Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer (NCT01649089) | GOG Foundation | 2013-06-05 |
| Oral Rigosertib for Squamous Cell Carcinoma (NCT01807546) | Traws Pharma, Inc. | 2013-03-01 |
| Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer (NCT01693783) | National Cancer Institute (NCI) | 2012-12-03 |
| Hybrid PET/MR in the Therapy of Cervical Cancer (NCT01759355) | UNC Lineberger Comprehensive Cancer Center | 2012-10-01 |
| Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix (NCT01365156) | M.D. Anderson Cancer Center | 2011-08-01 |
| Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer (NCT01266447) | National Cancer Institute (NCI) | 2011-02-01 |
| Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery (NCT01026792) | National Cancer Institute (NCI) | 2009-12-01 |
| Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer (NCT00803062) | National Cancer Institute (NCI) | 2009-04-01 |
| FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer (NCT00559377) | National Cancer Institute (NCI) | 2007-11-01 |
| Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer (NCT00054444) | Gynecologic Oncology Group | 2007-09-01 |
| Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer (NCT00416455) | National Cancer Institute (NCI) | 2007-09-01 |
| Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer (NCT00499031) | Gynecologic Oncology Group | 2007-06-01 |
| Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery (NCT00389974) | National Cancer Institute (NCI) | 2007-01-01 |
| ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer (NCT00309959) | Gynecologic Oncology Group | 2006-11-01 |
| Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer (NCT00262821) | National Cancer Institute (NCI) | 2006-02-01 |
| Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer (NCT00104910) | Gynecologic Oncology Group | 2005-01-01 |
| Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer (NCT00070317) | Gynecologic Oncology Group | 2004-06-01 |
| Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer (NCT00068549) | Gynecologic Oncology Group | 2003-10-01 |
| Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix (NCT00064077) | Gynecologic Oncology Group | 2003-05-01 |
| Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer (NCT00057863) | National Cancer Institute (NCI) | 2003-01-01 |
| Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix (NCT00025233) | National Cancer Institute (NCI) | 2002-04-01 |
| Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix (NCT00031993) | National Cancer Institute (NCI) | 2002-03-01 |
| Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia (NCT00017004) | Gynecologic Oncology Group | 2001-08-01 |